On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

AstraZeneca (Switzerland)

InstitutionResearch output, impact & collaborations

AstraZeneca (Switzerland) is a institution indexed in ScholarIQ from OpenAlex.

What is known about AstraZeneca (Switzerland)?

ScholarIQrecord summary

AstraZeneca (Switzerland) is a research organisation in Zug, CH. OpenAlex records 1,120 works and 46,224 citations for it. 689 researchers list it as their most recent affiliation.

How many works does AstraZeneca (Switzerland) have?

ScholarIQindexed works

AstraZeneca (Switzerland) has 1,120 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for AstraZeneca (Switzerland) →

How many citations does AstraZeneca (Switzerland) have?

ScholarIQcitation count

AstraZeneca (Switzerland) has 46,224 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for AstraZeneca (Switzerland) →

How many researchers are at AstraZeneca (Switzerland)?

ScholarIQresearcher count

AstraZeneca (Switzerland) has 689 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at AstraZeneca (Switzerland)?

ScholarIQavg h-index

AstraZeneca (Switzerland) has an average h-index of 37 in OpenAlex.

Open the OpenAlex record →

What is the ROR of AstraZeneca (Switzerland)?

ScholarIQror

The ROR for AstraZeneca (Switzerland) is on the source record.

Open the ROR →

What is the OpenAlex record for AstraZeneca (Switzerland)?

ScholarIQopenalex

The OpenAlex for AstraZeneca (Switzerland) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind AstraZeneca (Switzerland)?

ScholarIQtop researchers by citations

Richard Ofori‐Asenso · Health Systems, Economic Evaluations, Quality of Life

166 works63,388 citations

Juan José García Sánchez · Chronic Kidney Disease and Diabetes

166 works2,089 citations

What are the most-cited papers on AstraZeneca (Switzerland)?

ScholarIQmost cited works

Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial

Ramón C. Hermida, Juan J. Crespo, Manuel Domínguez-Sardiña, Alfonso Otero, Ana Moyá, María T. Ríos, Elvira Sineiro, M.C. Castiñeira, Pedro A. Callejas, Lorenzo Pousa, José Luis Bernal Salgado, Carmen Durán, Juan José García Sánchez, José R. Fernández, Artemio Mojón, Diana E. Ayala, for the Hygia Project Investigators

European Heart Journal. 2019456 CitationsOPEN ACCESS

Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme

Vivekanand Jha, Saeed Alghamdi, Guisen Li, Kwan‐Dun Wu, Panagiotis Stafylas, Lise Retat, Joshua Card-Gowers, Salvatore Barone, Claudia Cabrera, Juan José García Sánchez

Advances in Therapy. 2023271 CitationsOPEN ACCESS

Burden of Chronic Kidney Disease by KDIGO Categories of Glomerular Filtration Rate and Albuminuria: A Systematic Review

Molly Murton, Danielle Goff-Leggett, Anna Bobrowska, Juan José García Sánchez, Glen James, Eric Wittbrodt, Stephen Nolan, Elisabeth Sörstadius, Roberto Pecoits‐Filho, Katherine R. Tuttle

Advances in Therapy. 2020187 CitationsOPEN ACCESS

Asleep blood pressure: significant prognostic marker of vascular risk and therapeutic target for prevention

Ramón C. Hermida, Juan J. Crespo, Alfonso Otero, Manuel Domínguez-Sardiña, Ana Moyá, María T. Ríos, M.C. Castiñeira, Pedro A. Callejas, Lorenzo Pousa, Elvira Sineiro, José Luis Bernal Salgado, Carmen Durán, Juan José García Sánchez, José R. Fernández, Artemio Mojón, Diana E. Ayala, for the Hygia Project Investigators

European Heart Journal. 2018135 CitationsOPEN ACCESS

An analog front-end enables electrical impedance spectroscopy system on-chip for biomedical applications

Fernando Seoane, Javier Ferreira, Juan José García Sánchez, R. Bragós

Physiological Measurement. 2008101 CitationsOPEN ACCESS

How much of the research on AstraZeneca (Switzerland) is open access?

ScholarIQopen access share

100%OPEN ACCESS

Gold

18%

Green

18%

Hybrid

36%

Bronze

27%

Closed